Fig. 5From: Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinomaRisk score could predict the clinical benefits of immunotherapy and chemotherapy. A Comparison of the immune checkpoints genes between the high- and low-risk groups. B Correlation analyses of risk scores with immune checkpoint targets. Differences of the estimated IC50 of imatinib (C), Gefitinib (D), Sorafenib (E) and Cisplatin (F) between two risk groups in database. *: P < 0.05, **: P < 0.01, ***: P < 0.001Back to article page